NEW YORK (TheStreet) -- AbbVie (ABBV - Get Report) fell in pre-market trading on Monday after Irish biopharmaceutical company Shire (SHPG - Get Report) announced it would recommend a $53 billion takeover offer from the Humira maker, which could pave the road for one of the sector's largest mergers.
Chicago-based AbbVie offered a cash-and-stock deal equivalent to $91.10 a share for Shire over the weekend, which surpassed its previous offer of $51 billion. If completed, the deal would allow AbbVie to save millions of dollars in taxes via reincorporation in Britain, which has lower tax rates. Shire's headquarters are on the British island of Jersey.
Shire announced its shareholders would own approximately 25% of the combined AbbVie under the deal.
Must Read: Warren Buffett's 25 Favorite StocksSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. British regulators set a Friday, July 18 deadline to complete the deal. If it does not happen by that date, then AbbVie must abstain from negotiations for six months. AbbVie was down 2.73% to $53.46 in pre-market trading, while Shire was up 1.61% to $253.06. ABBV data by YCharts
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts